• Mutation; HGNC; HGNC:11998; TP53; Simple; c.280delTCA; Zygosity=Unspecified (PubMed=21084276).
  

PubMed=19890883; DOI=10.1002/path.2633; PMCID=PMC4058327
Subramanian S., Thayanithy V., West R.B., Lee C.-H., Beck A.H., Zhu S., Downs-Kelly E., Montgomery K.D., Goldblum J.R., Hogendoorn P.C.W., Corless C.L., Oliveira A.M., Dry S.M., Nielsen T.O., Rubin B.P., Fletcher J.A., Fletcher C.D.M., van de Rijn M.
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
J. Pathol. 220:58-70(2010)

PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799; PMCID=PMC3064267
Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R., Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J., Lev D.C.
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Cancer Res. 71:185-196(2011)

PubMed=25878149; DOI=10.1158/0008-5472.CAN-15-0675
Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R., Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J., Lev D.C.
Correction: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Cancer Res. 75:1771-1774(2015)

PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054
Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.
Genetics of human malignant peripheral nerve sheath tumors.
Neurooncol. Adv. 2:i50-i61(2020)